Sector News

Zymeworks could get up to $485M in expanded Daiichi I-O deal

May 15, 2018
Life sciences

When Zymeworks and Daiichi Sankyo initially teamed up on bispecific antibodies in 2016, they kept the financial details under wraps. Now, the pair is entering a new license agreement that could potentially be worth $484.7 million.

Under the original deal, Zymeworks licensed its Azymetric and Efect platforms to Daiichi Sankyo to develop a bispecific antibody therapy, for which Zymeworks is eligible to pick up milestone payments and royalties. It also received a license to certain immuno-oncology antibodies from Daiichi with the right to research, develop and market multiple bispecific products in exchange for royalties.

The new agreement sees the Vancouver-based biotech granting the Japanese pharma two more licenses for an upfront technology access fee of $18 million. It stands to receive up to $466.7 in clinical, regulatory and commercial milestones, with tiered royalties also up for grabs.

“Expanding our relationship with a leading global pharmaceutical partner like Daiichi Sankyo is extremely satisfying as it underscores the power, versatility and attractiveness of our technology platforms,” said Ali Tehrani, Ph.D., president and CEO of Zymeworks. “Having already used our platforms to discover one bispecific antibody, Daiichi Sankyo now has increased access to our technology to create additional therapeutic candidates. We are pleased to be working with a healthcare pioneer with a proven track record of over 100 years of innovation leading to major breakthroughs in patient care.”

The Azymetric technology works by doubling up on a drug’s potential target, offering a complementary approach to the Efect platform, a library of antibody Fc modifications that can be used to orchestrate an immune response: either turning it up or tamping it down.

Zymeworks has been on a dealmaking roll over the past few years. This includes an agreement with Janssen last November around six bispecific antibodies that saw it pick up $50 million up front, with another potential $282 million in development milestones and up to $1.12 billion in sales payments. Also in 2017, Zymeworks inked an R&D pact with The University of Victoria and BC Cancer Agency to develop engineered cytokine and cytokine receptor pairs.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach